Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2023-08-17
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
severe
assessed
2026-08-18
Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 15); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-20 (study day 21); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-05 (study day 36); relationship: N
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-11-15 (study day 77); relationship: Y
mild
assessed
2026-08-18
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-12-01 (study day 93); relationship: N
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-09 (study day 101); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.